At BTG we are focused on bringing to market innovative products in specialist areas of medicine to better serve doctors and patients. Our growing portfolio of Interventional Medicine products is designed to advance the treatment of cancer, severe emphysema, severe blood clots and varicose veins, while our Specialty Pharmaceuticals portfolio offers antidotes that alleviate toxicity and treat rare conditions.
Healthcare is constantly evolving – so BTG never stands still. Inspired by a deep understanding of our customers’ needs, we’re working to meaningfully improve the lives of patients and their healthcare experience.
Our competitive advantage is our dedication to finding smart, often unconventional solutions to complex medical problems. Many of our products combine medicines, device technology and new techniques in order to deliver more targeted treatments. We also invest in the clinical evidence to help demonstrate the value of our products to doctors, patients, and healthcare systems.
Doing what’s right for patients is what gets us to work in the morning. It’s part of our DNA. By staying true to this principle and our values, we’ve earned a strong reputation for the quality of our products and our commitment to innovation.
Whether developed in our own labs or in partnership with clinicians, academics and other companies, we believe passionately that medical innovation has the power to improve human health.
Imagine where we can go.
Company ProfileAbout Sanofi
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families. Learn more at www.sanofigenzyme.com
Sanofi, Empowering Life
Company ProfileAbout Exact Imaging
Exact Imaging (www.exactimaging.com) is the world’s leader in high-resolution micro-ultrasound systems enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Exact Imaging’s ExactVu™ micro-ultrasound platform operates at 29 MHz and enables a whole new level of resolution - - a 300% improvement over conventional ultrasound and resolution superior to MRI - - with the benefits of ease of use, affordability, and being an extension of the current urological workflow. Using the Exact Imaging platform, urologists are able to visualize areas of interest in the prostate and specifically target biopsies at those areas in real time, aided by the PRI-MUS™ (prostate risk identification using micro-ultrasound) evidence-based micro-ultrasound protocol. For the minority of cases where MRI might assist (i.e., prior negative biopsies), FusionVu™ is the forthcoming micro-US/MRI fusion application operating on the ExactVu micro-ultrasound platform. The ExactVu micro-ultrasound system has received regulatory approval in the European Union (CE Mark), the United States (FDA 510(k)) and Canada (Health Canada medical device license).
For more information, please contact:
Sales & Marketing Coordinator
Company ProfileAbout Siemens Healthineers
Siemens Healthineers is the separately managed healthcare business of Siemens AG enabling healthcare providers worldwide to achieve better outcomes at lower costs by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services.
Further information is available at www.healthcare.siemens.com
Company ProfileAbout AngioDynamics
AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products.
Visit us at booth#10 and find out more about the NanoKnife and the new Solero Microwave Tissue Ablation (MTA) systems.
More information is available at www.angiodynamics.com
Company ProfileAbout BK Ultrasound systems
BK Ultrasound systems are the gold standard for urology. New BK Fusion enhances your clinical findings with true, real-time MR-to-ultrasound fusion during prostate biopsy. bkFusion is a fully integrated application on the premium bk3000, it combines BK Ultrasound’s unmatched image quality with a streamlined, fast and intuitive fusion workflow. The bk3000 supports a wide range of advanced specialized transducers for urology including the unique triplane prostate transducer, which allows simultaneous biplane imaging and endfire imaging in one transducer, and a portfolio of transducers for kidney, bladder, testis and penile imaging.
More information is available at bkultrasound.com
Company ProfileAbout Clinical Laserthermia Systems (CLS)
Clinical Laserthermia Systems (CLS) develops, markets and sells the TRANBERG®|Thermal Therapy System and disposable single-use material that is used during treatment procedures. The TRANBERG system is developed for image guided high precision soft tissue thermal therapy and ablation procedures based on advanced laser technology. The system can be configured for MR or CT/US guided procedures using tissue temperature feedback for precise therapy and ablation control. The system includes a desk-top mobile laser unit, new innovative non- cooled laser applicators, external tissue temperature probe sensors and procedure specific accessories.
The products, based on innovative patented technology, are CEmarked for use in Europe and FDA-approved for use in the US market.
CLS focuses a large part of its efforts on clinical evaluation of the imILT® treatment protocol. imILT is based on research conducted by Professor Karl-Göran Tranberg and was developed to kill solid cancer tumors while stimulating an immunological defence against any remaining tumor cells. CLS is currently carrying out clinical studies of imILT in several sites Europe.
In the US market CLS products are targeting image guided laser ablation. Image guided laser ablation, performed using the TRANBERG®|Thermal Therapy System, is a focal therapy aimed at reducing morbidity and improving clinical outcome within interventional oncology and urology.
CLS employs a team of 15 highly skilled people, is headquartered in Lund, Sweden and has subsidiaries in Berlin, Germany and in Boston, USA. The company was founded in 2006 and is listed on Nasdaq First North (CLS B).
More information is available on www.clinicallaser.se
Company ProfileAbout EDAP TMS
Global leader in therapeutic ultrasound and present in the market for more than 35 years, EDAP TMS (NASDAQ: EDAP) develops, manufactures, promotes and distributes minimally-invasive medical devices for urology using ultrasound technology. EDAP TMS is actively operating worldwide via an extensive network of corporate offices, subsidiaries and distribution partners.
By constantly investing in Research & Development and partnering with internationally renowned medical research institutions, EDAP TMS has developed a strong valuable patent portfolio based on its innovative technologies.
With its complete range of Robotic HIFU devices, EDAP TMS is the most innovative company in minimally-invasive treatment for localized prostate cancer. By combining the latest technologies in imaging and treatment modalities, EDAP TMS introduced the Focal One® as the answer to all requirements for ideal focal therapy of prostate cancer as a complement to the existing Ablatherm® HIFU.
As a pioneer and key player in the field of extracorporeal lithotripsy (ESWL), EDAP TMS introduced the first modular lithotripter. The latest generation of shock wave source is utilized exclusively by EDAP TMS in its Sonolith® range of ESWL systems (Sonolith® i-sys and Sonolith® i-move).
More information is available on www.edap-tms.com
Company ProfileAbout Endocare, Inc.
Endocare, Inc. is a medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing cryoablation (freezing) technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets. With over 10-years of clinical experience in percutaneous, laparoscopic, and open cryoablation for prostate, kidney, and other tissues, we remain committed to innovative technology that improves and extends patients’ lives.
More information is available on www.healthtronics.com
Company ProfileAbout KOELIS
KOELIS, The Prostate Care Company, is a French multinational company that was founded in 2006 with the aim of addressing new challenges in urology. Based in Grenoble and Boston, KOELIS assists physicians worldwide in their routine clinical practice by providing the latest technology for personalized prostate cancer planning and management, from biopsy and treatment to active surveillance. Focused on developing advanced, targeted and less invasive solutions, KOELIS is committed to creating and bringing to the market a new paradigm in prostate cancer care, where physicians can offer the most personalized answers to their patients, avoiding any under or overtreatment and preserving their quality of life. KOELIS technology treats today more than 150,000 patients worldwide and has been published in more than 50 clinical reports. Being already present in more than 25 countries in every continent, KOELIS looks for becoming an international model in the prostate cancer sector with targeted diagnosis and treatment.
More information is available on www.koelis.com
Company ProfileAbout Profound Medical
Profound Medical is commercializing a novel technology, TULSA-PRO®, which combines real-time MRI with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control that is designed to provide precise ablation of the prostate while simultaneously protecting critical surrounding anatomy from potential side effects.
TULSA-PRO® is a promising modality for treatment of localized prostate cancer, as it enables incision-free and targeted ablation of prostate tissue. The millimetre precision, the ability to personalize the treatment to the patient’s anatomy & pathology, and the promise of providing a safe minimally-invasive solution with the potential to reduce side-effects, are key advantages of this technology.
TULSA-PRO® is CE marked and available commercially in the CE-marked jurisdictions. The Company is also sponsoring a multicenter, prospective FDA-registered clinical trial, TACT, which, if successful, is expected to support its application to the FDA for approval to market TULSA-PRO® in the United States.
More information is available at www.profoundmedical.com
Company ProfileAbout SonaCare Medical
SonaCare Medical is the leading innovator in minimally invasive ablation technology using high intensity focused ultrasound (HIFU). SonaCare Medical’s prostate tissue ablation system, Sonablate®500, incorporates MRI/US image fusion to provide a customized whole gland, hemi-gland, or focal prostate cancer treatment. Exclusive Sonablate fusion software fuses MRI images onto real-time US images in order to facilitate a precision-based ablation treatment plan, which helps to preserve quality of life functions in prostate cancer patients around the world. Sonablate is powered by the company’s pioneering multi-modal console, which allows for surgeons to incorporate additional treatment probes, including a laparoscopic device for soft tissue ablation. Please visit our booth to learn more about the latest innovations in HIFU therapy.
More information is available at www.sonacaremedical.com
Company ProfileAbout UC-CARE
UC-CARE is a medical device company that develops unique systems aimed to improve the care of prostate diseases. UC-CARE’S systems are solving the problem of blind biopsy and providing an improved plan for the focal treatment and active surveillance of the disease.
UC-CARE’s Navigo system, a real time automated 3D fusion navigation system compatible to the ultrasound system of choice and the preferred clinical setup by the physician. SmartBx is a one-of-a-kind biopsy specimen management system, that streamlines the tissue downloading in a semi-automatic 2-step function reducing human error and increasing precision.
More information is available at www.uc-care.com
Company ProfileAbout VARIAN
Varian Medical Systems, Inc., of Palo Alto, California, focuses energy on saving lives by equipping the world with advanced technology for fighting cancer.
The company is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian Medical Systems employs approximately 6,400 people at sites around the world. For more information, visit www.varian.com and follow @VarianMedSys on Twitter.
Company ProfileAbout Progenics
Progenics Pharmaceuticals, Inc. develops innovative medicines and imaging analytical tools to target and treat cancer. Progenics' pipeline includes: 1) therapeutic agents designed to precisely target cancer (AZEDRA® and 1095), 2) PSMA-targeted imaging agents for prostate cancer (1404 and PyL™), and 3) imaging analysis tools. Progenics' first commercial product, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with Valeant Pharmaceuticals International, Inc.
More information is available at www.progenics.com